Biguanides are classified as peripheral insulin sensitizers that work by decreasing hepatic glucose production and absorption from food. They are available as liquids, tablets, and extended-release tablets taken one to three times daily with meals depending on the formulation. Common adverse effects include gastrointestinal distress like diarrhea, cramps, nausea and vomiting. Nursing considerations include monitoring blood glucose, laboratory tests, and symptoms to evaluate effectiveness, glycemic control, and potential toxicity.
Biguanides are classified as peripheral insulin sensitizers that work by decreasing hepatic glucose production and absorption from food. They are available as liquids, tablets, and extended-release tablets taken one to three times daily with meals depending on the formulation. Common adverse effects include gastrointestinal distress like diarrhea, cramps, nausea and vomiting. Nursing considerations include monitoring blood glucose, laboratory tests, and symptoms to evaluate effectiveness, glycemic control, and potential toxicity.
Biguanides are classified as peripheral insulin sensitizers that work by decreasing hepatic glucose production and absorption from food. They are available as liquids, tablets, and extended-release tablets taken one to three times daily with meals depending on the formulation. Common adverse effects include gastrointestinal distress like diarrhea, cramps, nausea and vomiting. Nursing considerations include monitoring blood glucose, laboratory tests, and symptoms to evaluate effectiveness, glycemic control, and potential toxicity.
Biguanides are classified as peripheral insulin sensitizers that work by decreasing hepatic glucose production and absorption from food. They are available as liquids, tablets, and extended-release tablets taken one to three times daily with meals depending on the formulation. Common adverse effects include gastrointestinal distress like diarrhea, cramps, nausea and vomiting. Nursing considerations include monitoring blood glucose, laboratory tests, and symptoms to evaluate effectiveness, glycemic control, and potential toxicity.
Download as DOCX, PDF, TXT or read online from Scribd
Download as docx, pdf, or txt
You are on page 1of 1
Drug name Classification of Mechanism route Timing Adverse effect Nursing
drug of action considerations
Biguanides Biguanides Biguanides Oral Biguanides biguanides is -Monitor decrease work in the are gastrointestinal blood glucose hepatic glucose following available distress, levels as production— ways: They as liquid, including ordered to both reduce the tablets, diarrhea, evaluate gluconeogenesis production and cramps, effectiveness and of glucose extended- nausea, of drug and glycogenolysis— during release vomiting, and glycemic to lower plasma digestion (long- increased control. glucose. They by acting) flatulence [72]. -Monitor are classified as decreasing tablets. Long-term use results of peripheral the amount The liquid of biguanides laboratory insulin of glucose is taken has been tests, sensitizers. absorbed with meals associated with including from the one or two decreased urinalysis, for food. They times a absorption of evidence of prevent the day. The vitamin B12 glycosuria, liver from regular and renal and converting tablet is liver function fats and taken with tests, to amino meals two determine the acids into or three need for glucose. times a possible dose They day, and adjustment increase the and evaluate the extended- for signs of excretion release toxicity. of sugar by tablet is the kidneys taken once daily with the evening mea